The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
News|Articles|September 12, 2025
AJMC® in the Press, September 12, 2025
Author(s)Julia Bonavitacola
Fact checked by: Christina Mattina
Listen
0:00 / 0:00
Key Takeaways
- Increased primary care visits correlate with reduced healthcare expenditures, especially for patients with higher clinical complexity.
- Regular primary care engagement may serve as a cost-effective strategy for managing complex health needs.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
An article published in
Advertisement
Related to this article
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.
A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Bumetanide nasal spray is bioequivalent to oral bumetanide in 68 healthy adults; Esperion is targeting heart failure care before a 2027 CMS payment model.
The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
3
FDA Approves First Symptomatic Dermographism Treatment
4
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
5